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Hemoglobin (Hb)-based oxygen carriers (HBOCs) are being
developed as resuscitative fluids for use in multiple medical
applications and in lieu of blood transfusion. However, cardiovas-
cular, central nervous system, and renal adverse events have
largely impeded progress. This has prompted a need to evaluate
novel down selection approaches for HBOCs prior to in-depth
preclinical and clinical safety testing. In the present study,
polymerized bovine Hbs (PolybHbs) were prepared with
increasing ratios of glutaraldehyde to bovine Hb (10:1, 20:1,
30:1, and 40:1). The optimal PolybHb candidate selection was
based on a priori determined in vivo response to include a long
circulating PolybHb with no measurable renal exposure, minimal
cardiovascular response, limited oxidation to metHb in vitro, or in
circulation and absence of acute end organ toxicity. Guinea pigs
were dosed via a 50% blood for PolybHb exchange transfusion.
Data suggested that the 30:1 preparation exhibited maximum
circulatory exposure (AUC0–N) with the lowest level of oxidation
(plasma metHb formation) and minimal (< 10%) blood pressure
elevation. Additionally, the 30:1 preparation was absent renal iron
deposition as well as abnormal glomerular/tubular histopathology
or serum creatinine elevation. Clearance pathways predominantly
followed those consistent with endogenous Hb clearance based
pathways. Therefore, data confirmed the ability to select a single
PolybHb from a small library of HBOCs based on a priori
determined characteristics. Moreover, the approach to down
selection described could be applied to enhance the early
predictability of human safety for this class of biological
therapeutics to optimize for specific indications.
Key Words: hemoglobin; polymerized hemoglobin; red blood cell
substitute; transfusion medicine; oxygen therapeutic;
pharmacokinetics/pharmacodynamics; toxicity.
Hemoglobin (Hb)-based oxygen carriers (HBOCs) represent
a class of biological therapeutics that have been studied in
multiple disease state clinical trials when blood volume
replacement and oxygen delivery are required (Silverman and
Weiskopf, 2009). Disease states studied include traumatic and
surgical blood loss, cardiac bypass, stroke, myocardial infarction,
and sickle cell anemia. Additionally, these agents are approved
in certain countries for use in lieu of blood transfusion due to
either shortage or donor blood safety concerns.
In the United States, several HBOCs have been evaluated
clinically under regulatory supervision; however, none have been
approved for licensure. The primary regulatory issues with
HBOCs stem from unacceptable safety profiles in clinical trials
that indicate an increased risk to benefit ratio (Silverman and
Weiskopf, 2009). The primary safety signals observed suggest
increased severe adverse events associated with the cardiovas-
cular system, central nervous system, and kidneys. The
mechanisms of these toxicities are not well defined; however,
the primary focus has been on the nitric oxide (NO)–depleting
effects of Hb, which can lead to hypertension and vascular
dysfunction (Yu et al., 2009). An equally important mechanism
of Hb toxicity involves oxidation of heme within the protein,
which can lead to free radical generation and finally heme and
iron release (Buehler et al., 2007; Butt et al., 2010). The primary
effects can be acute and localized tissue injury, particularly in
organ systems experiencing extensive exposures.
HBOCs were often developed as single entity molecules for
intended use in multiple and diverse indications. Development
strategies have focused on chemical and recombinant modifi-
cation of Hb, however, limited examples exist where in vivo
studies were employed in a multicandidate down selection
process. In a series of papers focused on recombinant-based
heme pocket re-engineering intended to minimize heme iron’s
interaction with NO, one can find a description of extensive
recombinant and biochemical efforts followed by a limited
in vivo screening analysis (Doherty et al., 1998; Dou et al.,
Disclaimer: The findings and conclusions in this article have not been
formally disseminated by the Food and Drug Administration and should not be
construed to represent any Agency determination or policy.
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2002; Olson et al., 2004). As part of these studies, libraries of
modified proteins were evaluated and down selected based on
hemodynamic response in rats. Particular focus was placed on
systemic vasoconstriction, and the choice of engineered Hb
was based on the rate of NO dioxygenation determined in vitro
and vascular resistance determined in vivo.
The down selection of an appropriate product candidate for
preclinical and later clinical trial evaluation may further benefit
from initial evaluation of libraries of product candidates to include
early assessment of pharmacokinetics (PKs), hemodynamics,
oxidation, and toxicological responses in vivo. We have
developed and evaluated a library of four molecular sized bovine
hemoglobins (bHb) polymerized with glutaraldehyde and
collectively termed PolybHb. PolybHbs were synthesized with
cross-link densities (i.e., molar ratio of glutaraldehyde to bHb) of
10:1, 20:1, 30:1, and 40:1 according to a previously described
methodology reported in the literature (Zhou et al., 2011). Within
the context of this study, the PolybHbs function as a group of
identically prepared HBOCs with the single variable in their
preparation being the glutaraldehyde to bHb polymerization ratio.
This allowed us to study the effects of modified Hbs with
identical starting material and modifying agent on a priori
determined in vivo characteristics. In the present set of experi-
ments, the four PolybHbs were evaluated for PK characteristics
(metabolism, distribution, and excretion), safety pharmacology
(systemic blood pressure response), in vitro and in vivo oxidation,
and potential for tissue-based toxicity (acute renal toxicity). Our
criteria for meeting selection included a long circulating modified
Hb with minimal breakdown in circulation, no renal excretion,
limited hypertensive response, minimal potential for oxidation,
and no initial evidence of renal tissue toxicity (renal iron
deposition, histological changes, or increases in serum creatinine).
We additionally suggest that this type of approach could serve as
a novel method to down select HBOCs early in their development
using a priori determined in vivo attributes that may be applicable
to use specific indications.
MATERIALS AND METHODS
Materials
Glutaraldehyde (70%), NaCl, KCl, NaOH, Na2S2O4, NaCl (USP), KCl
(USP), CaCl2-2H2O (USP), NaOH (NF), sodium lactate (USP), N-acetyl-L-
cysteine (USP), NaCNBH3, and NaBH4 were purchased from Sigma-Aldrich
(Atlanta, GA). One hundred and five hundred kilodalton hollow fiber cartridges
were purchased from Spectrum Labs (Rancho Dominguez, CA). KCN,
K3Fe(CN)6, and all other chemicals were purchased from Fisher Scientific
(Pittsburgh, PA). In preparation for experiments, all glassware and plasticware
were immersed in 1 mol/l NaOH solution for more than 6 h to degrade any
endotoxin present, followed by thorough rinsing with high performance liquid
chromatography (HPLC) grade water (the mean conductivity value being 18.2
3 106 Xcm). bHb was prepared from fresh bovine red blood cells (RBCs)
stored in 3.8% sodium citrate solution at a final concentration of 90:10 vol/vol
(bovine blood:sodium citrate solution). Bovine RBCs were purchased from
Quad Five (Ryegate, MO). bHb was purified from lysed bovine RBCs via
tangential flow filtration (TFF) as described in the literature (Palmer et al.,
2009).The endotoxin level of bHb was measured using a Limulus amebocyte
lysate (LAL) test kit (Pyrogent Plus, Lonza, Walkersville, MD). When diluted
for polymerization with glutaraldehyde, bHb demonstrated acceptable
endotoxin levels ( 0.5 EU/ml). These data are also consistent with a previous
report from our laboratory (Elmer et al., 2009).
Polymerization of bHb
PolybHbs were synthesized according to a previously described methodology
in the literature (Zhou et al., 2011). In brief, four different molecular sized
PolybHbs were prepared using increasing molar ratios of glutaraldehyde:bHb (10,
20, 30, and 40:1). To generate fully deoxygenated bHb, 30 g of purified bHb was
diluted with phosphate buffer (PB) (20mM, pH 8.0) to yield 1200 ml of bHb
solution. The bHb solution was placed inside an airtight bottle and connected to
a vacuum manifold. The entire system was kept below 4C in an ice water bath.
The bHb solution was then subjected to several cycles of vacuum and argon (Ar)
purging to remove the majority of O2 from solution. After 4 h of vacuum and Ar
cycling, Na2S2O4 solution (1.5 mg/ml) was titrated into the bHb solution with
a syringe pump (Razel Scientific, St Albans, VT), while the pO2 of the solution
was simultaneously measured using a RapidLab 248 (Siemens, Malvern, PA)
blood gas analyzer until the partial pressure of O2 (pO2) in the bHb solution
attained a value of 0 mm Hg. At this point, an additional 30 ml of 1.5 mg/ml
Na2S2O4 solution was added to the deoxygenated bHb solution to maintain the
pO2 at 0 mm Hg during and after the polymerization reaction. A 30 ml syringe
was used to titrate deoxygenated glutaraldehyde solution pre-equilibrated with Ar
into the deoxygenated bHb solution at the following molar ratios of
glutaraldehyde to bHb: 10:1, 20:1, 30:1, and the 40:1. Polymerization reaction
was kept under continuous stirring at 37C in the dark with Ar purging for 2 h,
and the polymerization reaction was terminated with the addition of 20 ml of 2M
NaBH4 in PB buffer (20mM, pH 8.0).
Clarification and Diafiltration of PolybHb Solution
The resulting PolybHb solutions were initially clarified by filtering them
through a column packed with autoclaved glass wool in order to remove large
particles. The clarified PolybHb solution was then diluted from 1500 to 2000 ml
and then subjected to four cycles of diafiltration via TFF against an ice-cold
modified lactated Ringer’s solution (NaCl 115 mmol/l, KCl 4 mmol/l, CaCl2-
2H2O 1.4 mmol/l, NaOH 13 mmol/l, sodium lactate 27 mmol/l, and N-acetyl-L-
cysteine 2 g/l). One hundred kilodalton HF cartridges were used for diafiltration
of the PolybHb solutions with a glutaraldehyde:bHb molar ratio of 10:1,
whereas 500 kDa HF cartridges were employed for PolybHb solutions with
glutaraldehyde:bHb molar ratios of 20:1, 30:1, and 40:1. For each diafiltration
cycle, the PolybHb solution was concentrated to a volume less than 200 ml. At
the end of diafiltration, the endotoxin level of PolybHb was measured using an
LAL test kit (Pyrogent Plus). Increased viscosity leads to a falsely high LAL
value given that the assay is based on measurement of clot formation. As a result,
each solution required dilution to prepolymerization (25 mg/ml) levels. When
diluted to prepolymerization concentrations PolybHbs demonstrated acceptable
endotoxin levels ( 0.5 EU/ml). At the final diafiltration step, the resulting
concentrated PolyHb solution was immediately stored at 80C for future use.
MetHb Level and Protein Concentration of PolybHb Solutions
The metHb level of PolybHb solutions was measured via the cyanomethe-
moglobin method (Oser, 1965). Total protein concentration was measured
using the Bradford (1976) method using the Coomassie Plus protein assay kit
(Pierce Biotechnology, Rockford, IL).
Size Exclusion Chromatography Coupled With Multiangle Static Light
Scattering Analysis of PolybHb Solutions
The absolute molecular weight distribution of bHb/PolybHb solutions was
measured using a size exclusion chromatography (SEC) column (Ultrahydrogel
linear column, 10 lm, 7.8 3 300 mm; Waters Corp., Milford, MA) driven by
a 1200 HPLC pump (Agilent, Santa Clara, CA), controlled by Eclipse 2 software
(Wyatt Technology, Santa Barbara, CA) connected in series to a DAWN Heleos
(Wyatt Technology) light scattering photometer and an OptiLab Rex (Wyatt
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Technology) differential refractive index detector. The mobile phase consisted of
20mM PB (pH 8.0), 100 ppm NaN3, and 0.2M NaCl (Fisher Scientific) in HPLC
grade water that was filtered through a 0.2 lm membrane filter. PolyHb solutions
were diluted to 1 mg/ml with the mobile phase, and 60 ll of sample was injected
onto the column via a 1200 Autosampler (Agilent). All data were collected and
analyzed using Astra 5.3 (Wyatt Technology) software.
In Vitro Autoxidation of PolybHb Solutions
All PolybHb samples were 95% ferrous (Fe2þ) or oxy-PolybHb immediately
prior to autoxidation experiments. Experiments were carried out with 20–25lM
heme in sealed cuvettes with room air equilibrated with 50mM Chelex-treated
potassium phosphate buffer at 37C. Absorbance changes in the range of 450–700
nm due to spontaneous oxidation of Hb were recorded in a temperature-controlled
photodiode array spectrophotometer (Hewlett Packard 8453, Palo Alto, CA).
Similar oxidation assays were also performed in the presence of superoxide
dismutase (4.6 U/ml) and catalase (414 U/ml). Autoxidation reactions were
followed to near completion (~24 h), at which time 22lM potassium ferricyanide
(K3Fe(CN)6) was added to completely oxidize the remaining ferrous PolybHb.
A multicomponent analysis was performed to calculate the ferrous and ferric
species based on their individual extinction coefficients. Autoxidation rates were
obtained from plots of the loss of ferrous to ferric PolybHb versus time using
nonlinear least-squares curve fitting (single-exponential, two parameter decay)
techniques in Sigma-Plot (SPSS, Chicago IL).
Animals, Surgical Preparation, and Experimental Design
Male Hartley guinea pigs were purchased from Charles Rivers Laboratories
(Wilmington, MA) and acclimated for 1 week upon arrival to the Food and Drug
Administration (FDA)/Center for Biologics Evaluation and Research (CBER)
animal care facility. All animals were fed normal diets throughout the acclimation
period and weighed 350–450 g at the time of study. Animal protocols were
approved by the FDA/CBER Institutional Animal Care and Use Committee with
all experimental procedures performed in adherence to the National Institutes of
Health (NIH) guidelines on the use of experimental animals. Surgical preparation
was performed as described previously in the literature (Buehler et al., 2007).
Fully conscious and freely moving guinea pigs were randomized to receive a 50%
blood for 10:1, 20:1, 30:1, or 40:1 PolybHb (n ¼ 5–6 guinea pigs per group)
volume exchange transfusion (ET) based on the equation for determining blood
volume in the species (Ancill, 1956) (50% ET (ml) ¼ (0.07 (ml/g) 3 body
weight (g))/2). Plasma from blood in the heparinized withdrawal syringe for each
transfused animal was obtained to determine the total PolybHb removed during
the ET period (approximately 12 min). Each PolybHb solution was transfused as
a 100 mg/ml protein solution. Blood samples (0.2 ml) were obtained from the
arterial catheter prior to infusion (baseline) and at the end of ET (time 0), and at
0.25, 0.5, 1, 2, 4, 8, 12, 24, 36, 48, 60, 72, and 96 h, or until plasma became
cleared of PolybHb. Urine was collected using standard rodent metabolic cages
under ice at 3 h intervals over the initial 24 h period then for 3 h daily until
PolybHb was no longer observed in plasma at designated blood sampling
intervals. Plasma was used for evaluation of: (1) total PolybHb, (2) ferrous (Fe2þ)
PolybHb, and (3) ferric (Fe3þ) PolybHb using a photodiode array spectropho-
tometer (Model 8453 Hewlett Packard) (Evelyn and Malloy, 1938). The
circulating PolybHb polymer distribution in plasma and excreted in urine was
evaluated as a function of time using a previously described method in the
literature (Buehler et al., 2007). Plasma and pooled urine samples (50 ll) were
additionally evaluated by SEC run on a BioSep-SEC-S3000 (6003 7.5 mm) SEC
column (Phenomenex, Torrance, CA) attached to a Waters Delta 600 pump and
Waters 2499 dual-wavelength detector, controlled by a Waters 600 controller
using Empower2 software (Waters Corp.).
In a separate group of animals (n ¼ 4), the right femoral artery was also
catheterized with PE10 tubing fused to PE50 tubing to allow for simultaneous
administration of PolybHb and monitoring of arterial blood pressure (systolic,
diastolic, and mean) and heart rate (HR). The right carotid artery catheter was
connected to a Gould P23 XL pressure transducer (Gould Instrument System
Inc., Valley View, OH) for recording blood pressure. Arterial blood pressure
was recorded continuously at 100 Hz using a MP100A-CE data acquisition
system (Biopac Systems, Inc., Santa Barbara, CA). Data were analyzed off-line
using AcqKnowledge software (Biopac Systems, Inc.) to determine the mean
arterial pressure (MAP) from the following formula (diastolic þ 1/3 [systolic
diastolic]) with each being averaged over consecutive minutes of acquired data.
PK Analysis of PolybHb Solutions
The dose (mg) of PolybHb received by each animal at the end of ET was
determined as previously described for ET based PK studies (Buehler et al.,
2004, 2007). Briefly, the total amount of PolybHb in the plasma from whole
blood collected in the ET syringe from the total amount of infused PolybHb
according to the following equation:
dosereceived ¼

½PolybHbinfused3Vinfused



½PolybHbtotal ET3VET

Where doseinfused is the concentration of PolybHb (mg/ml) infused, Vinfused is
the PolybHb infusion volume (ml), [PolybHb]total ET is the concentration of
PolybHb (mg/ml) from plasma sampled out of the withdrawal syringe, and VET
is the volume (ml) collected in the withdrawal syringe.
PK parameters were determined for total PolybHb, ferrous PolybHb (oxy/
deoxy), and ferric PolybHb from plasma at each blood collection time point.
Noncompartmental methods employed by WinNonlin version 5.2.1 (Pharsight
Corp., Mountain View, CA) were used to calculate PK parameter estimates. The
area under the plasma concentration time curve (AUC0–N) was estimated using
the linear trapezoidal rule to the last measurable concentration (AUC0–Clast) where
Clast is the last measurable plasma concentration. Extrapolation to infinity
(AUCClast–N) was calculated by dividing Clast by the negative value of the
terminal slope (k) of the log-linear plasma concentration-time curve. Thus,
AUC0–N is equal to the sum of AUC0–Clast and AUCClast–N. Additional
parameters were calculated as follows: the plasma clearance (CL) was calculated
as the dose divided by AUC0–N, the mean residence time (MRT) was calculated
as k1, the volume of distribution (Vdss) was calculated as the product of CL and
MRT, and half-life (t1/2) was calculated as ln(2) divided by k.
Western Blot Analyses
Kidney lysates were resolved on 4–12% Bis-Tris gels, transferred to
polyvinylidene fluoride membranes, and blocked for 1 h in Tris-buffered saline
and Tween-20 (TBS-T) with 5% nonfat dry milk. Membranes were incubated
overnight at 4C with an antibody to HO-1 (1:2000) Calbiochem (San Diego,
CA). Rabbit polyclonal anti-HO-1 (cat# SPA-894) washed and then incubated
with a relevant horseradish peroxidase–conjugated secondary antibody for 1 h.
The signal was developed using an ECL Plus kit and detected on HyperECL
film (GE Healthcare, Piscataway, NJ). Membranes were stripped and reprobed
for b-actin. Densitometry analysis was performed using ImageJ software (NIH,
Bethesda, MD) with normalization to actin.
Tissue Iron Measurements
Kidney, liver, and spleen tissue (100 mg) were homogenized in double
deionized H2O at 1:10 wt/vol. Homogenates were mixed with 500 ll of an acid
mixture containing 1mM HCl and 10% Trichloroacetic acid (TCA), and incubated
at 50C for 1 h with intermittent shaking (Carter, 1971). The samples were then
centrifuged at 15,000 3 g for 15 min at room temperature. The clear supernatant
(90 ll) was mixed with 30 ll of 20 mg/ml ascorbic acid followed by 20 ll of
ferrozine (0.85% wt/vol in hydroxylamine hydrochloride). The samples were
allowed to completely develop for 30 min. The absorbance was measured at
560 nm using the Synergy 4 Hybrid Multi-Mode microplate reader (Biotek,
Winooski, VT). A standard curve was generated using an iron standard (500 lg/dl).
Histopathology and Immunohistochemistry
Hematoxylin and eosin histopathology. Kidneys were fixed in 10%
formalin, embedded in paraffin, and 5 lm sections were cut and stained
by standard hematoxylin-eosin (H/E) procedures. Tissues were scored
using a semiquantitative grading system as follows: 0 ¼ minimal, 1 ¼ mild,
2 ¼ moderate, 3 ¼ severe (minimal indicates a detectable process but barely
present, mild: small aggregates of inflammatory or necrotic cells, moderate:
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large aggregated inflammatory or necrotic cells at 2003, and severe: large
multifocal aggregates making up greater than 50% of the tissue area).
Nonheme iron histopathology. Kidneys, livers, and spleens were fixed in
10% formalin, embedded in paraffin, and 5 lm sections were prepared. Sections
were dewaxed in xylene and rehydrated in graded ethanol and deionized water.
Nonheme ferric iron deposition was detected using Perls method with
diaminobenzidine (DAB) intensification (Meguro et al., 2007). Sections were
incubated with Perls iron reagent containing 5% potassium ferrocyanide and 2%
hydrochloric acid for 45 min at room temperature and rinsed in deionized water.
Sections were then incubated with 0.3% hydrogen peroxide and 0.01M sodium
azide in methanol for 30 min at room temperature. All sections were then rinsed
in 0.1M PB, pH 7.4, incubated with DAB for 5 min, washed in deionized water,
and lightly counterstained with Gill’s II hematoxylin.
Heme oxygenase-1 immunohistochemistry. Sections were dewaxed in
xylene and rehydrated in graded ethanol and deionized water. Antigen retrieval
was performed by heat treatment in a microwave oven for 15 min in 10mM
sodium citrate buffer (pH 6.0), cooled for 30 min at room temperature, and rinsed
with deionized water and PBS containing 0.05% Tween-20 (PBS-T). Sections
were incubated with 3% H2O2 in PBS-T for 15 min at room temperature.
Sections were blocked with PBS-T containing 10% normal horse or goat serum
and 0.25% Triton-X for 1 h at room temperature followed by incubation with
primary antibodies to HO-1 (1:400) overnight at 4C. The signal was developed
with peroxidase-conjugated avidin-biotin complexes (Vectastain Elite ABC,
Vector Labs) and diaminobenzidine (SigmaFast DAB, Sigma). Slides were
washed with double deionized water, counterstained with hematoxylin, rinsed,
and dehydrated in graded ethanol and xylene. Images of the kidney, liver, and
spleen were obtained using an Olympus IX71 inverted microscope (340 and
3400 magnification).
Surface Plasmon Resonance
Haptoglobin binding to each of the PolybHbs was performed by coupling
10 lg of Hp 1-1 in acetate buffer pH 4.0 to a ProteOn sensor chip (Bio-Rad,
Hercules, CA) in a ProteOn XPR36 system. Chip conditioning was done with
the following injection sequence: 0.5% SDS, 50mM NaOH, and 100mM HCl
all at a flow rate of 30 ll/min. Each PolybHb was run at a flow rate of 100 ll/min
with a contact time of 60 s and dissociation time of 1800 s. Decreasing
concentrations (4, 2, 1, 0.5 and 0.25 lM) of each PolybHb solution in 200 ll of
ProteOn running buffer was passed over the chip. Chip regeneration was
performed with 1.6M glycine/HCl.
Statistical Analysis
All data are expressed as the mean ± SEM. Statistical comparisons were
performed by a one-way ANOVA with an a priori test for planned comparisons
followed by a post hoc Bonferroni’s test for determination of group differences.
In all analyses, a value p < 0.05 was taken as the level of statistical significance.
RESULTS
Polymerized Hemoglobin Molecular Sizes
Figure 1 and Table 1 show the SEC coupled with multiangle
static light scattering (MASLS) analysis of molecular sizes
generated by reacting a range of glutaraldehyde concentrations
with bHb. Ratios of polymerization agent to bHb are indicated
over a range from 10:1 to 40:1, and molecular size is expressed
as kilodalton (kDa).
PK Analysis
Table 2 shows the PK parameter estimates for total PolybHb,
ferrous (Fe2þ) PolybHb, and ferric (Fe3þ) PolybHb following
50% PolybHb for blood ETs. All guinea pigs received
comparable doses at the end of transfusion based on our
calculation described in the Materials and Methods section.
Figure 2 shows the data used to define noncompartmental PK
parameter estimates plotted as the mean ± SEM plasma
concentration versus time. Total PolybHb (ferrous, Fe2þ and
ferric, Fe3þ) estimates for the terminal half-life (t½b) indicate
significant differences between PolybHb 30:1 being nearly
twofold greater than PolybHbs 20:1, 10:1, and 40:1. The
primary exposure parameters Cmax, AUC0–N, and total Cl
demonstrated significantly lower Cmax values following ET
with PolybHb 10:1. This finding is directly related to rapid
renal filtration and clearance as evidenced by increased urinary
Hb observed during transfusion and over the time course of
urine collection. AUC0–N was significantly higher following
ET with PolybHb 30:1 compared against PolybHbs 20:1 and
10:1. These data suggest a twofold greater circulatory exposure
following transfusion with PolybHb 30:1. Total Cl was
significantly slower following ET with PolybHb 30:1 consis-
tent with a twofold slower rate compared with PolybHbs 20:1
and 10:1. Taken together, this data suggest a greater circulatory
exposure following ET with PolybHb 30:1 compared with
either PolybHb 10:1 or 20:1. Interestingly, dosing with the
PolybHb 40:1 preparation, the largest molecular sized
FIG. 1. Absolute molecular weight distribution of unmodified bHb and
PolybHb solutions. The weight averaged molecular weight of each solution is
listed in Table 1.
TABLE 1
Weight Averaged Molecular Weight (MW) of Polymerized
Hemoglobin Solutions
Solution MW (kDa)
bHb 65.3 ± 0.6
10:1 PolybHb 91 ± 10
20:1 PolybHb 749 ± 43
30:1 PolybHb 1330.3 ± 159
40:1 PolybHb 5494.6 ± 362
Note. SDs represent reactions run in triplicate.
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PolybHb, demonstrated PK parameters that were comparable to
the PolybHb 20:1 preparation and therefore suggest a nonlinear
PK dependence on molecular size. These data suggest that
molecular size exceeding 2000 kDa may promote faster
clearance and reduced exposure times. Therefore, we did not
continue to extensively pursue this preparation in the remaining
experiments.
PolybHb Component Plasma Distribution
SEC chromatographs of plasma from guinea pigs are shown
in Figures 3A–C. The time course of blood collection shows
a rapid loss of Hb tetramer from the plasma of 10:1 PolybHb-
transfused animals (Fig. 3A). The 72-h pooled urine collection
suggest that a large quantity of this component is excreted
renally (Fig. 3D). The multitetrameric PolybHb components
within the 20:1 and 30:1 PolybHb preparations appear to have
remained in circulation for an extended period of time
(Figs. 3B–C). Gradual metabolism/clearance clearly occurred
over 72–96 h with the largest fractional components circulating
at significant plasma levels for as long as 48 and 72 h for the
20:1 and 30:1 PolybHb preparations, respectively. From the
SEC data shown in Figure 3D, pooled urine samples suggest
minimal excretion of globin from either the 20:1 or 30:1
PolybHb preparations. Taken together with the pharamacoki-
netic data, this evaluation suggests that optimal circulatory
retention of PolybHb in this study occurs in the 20–30:1
polymerization range.
Safety Pharmacology
In vitro and in vivo oxidation. The rates of in vitro
autoxidation (kox, per hour) are shown in Table 3. In Figure 4A,
the percent of sample autoxidized after 6 and 24 h at 37C is
shown. The data demonstrate a significantly lower in vitro
autoxidation at both 6 and 24 h of incubation for the 30:1
PolybHb group compared with the 10:1 and 20:1 PolybHb
groups. This in vitro data were consistent with in vivo data
evaluating heme iron oxidation and suggesting maximum
plasma ferric (Fe3þ) PolybHb occurring between 8 and 12 h
posttransfusion (Fig. 4B). Levels reached as high 52 ± 3.0% of
the total circulating plasma PolybHb concentration in the 20:1
PolybHb group. Maximal in vivo oxidized plasma PolybHb
TABLE 2
PK Parameter Estimates of PolybHbs (10:1, 20:1, 30:1, and 40:1) Following a 50% Exchange Transfusion
Estimate Total Hb Hb(Fe2þ) Hb(Fe3þ)
PolybHb (10:1)
Dose (mg) 1282 ± 96 1252 ± 89 31 ± 11
Cmax (mg/ml) 22.0 ± 1.8 17.8 ± 1.4 6.9 ± 2.6 at Tmax ¼ 1.0 h
AUC0–N (mg h/ml) 206 ± 5.9 159 ± 9.6 46 ± 4.9 ( 22 ± 2.8% total AUC0–N)
Cltotal (ml/h) 6.3 ± 0.6 8.0 ± 1.0
Vd (ml) 108 ± 14 128 ± 15
t1/2 b (h) 10.9 ± 0.3 10.6 ± 0.6
PolybHb (20:1)
Dose (mg) 1375 ± 17 1341 ± 21 47 ± 5.0
Cmax (mg/ml) 28.9 ± 1.7 18.9 ± 1.3 11.4 ± 5.0 at Tmax ¼ 5.5 h
AUC0–N (mg h/ml) 682 ± 86 271 ± 40 358 ± 20 (46 ± 1.3% total AUC0–N)
Cltotal (ml/h) 2.0 ± 0.10 3.7 ± 0.01
Vd (ml) 54 ± 3.2 89 ± 1.7
t1/2 b (h) 19 ± 2.0 13.5 ± 0.30
PolybHb (30:1)
Dose (mg) 1076 ± 80 1036 ± 82 40 ± 5.0
Cmax (mg/ml) 31.9 ± 4.0 29.1 ± 4.1** 6.7 ± 0.96 at Tmax ¼ 4.5 h
AUC0–N (mg h/ml) 1126 ± 74**
,* 750 ± 62**,* 375 ± 56 (33 ± 3.9% total AUC0–N)
Cltotal (ml/h) 0.90 ± 0.2**
,* 1.4 ± 0.2**,*
Vd (ml) 39 ± 6.8**,* 50 ± 11**,*
t1/2 b (h) 31.1 ± 1.7**
,* 23.5 ± 1.8**,*
PolybHb (40:1)
Dose (mg) 1259 ± 20 1244 ± 37 43 ± 2.8
Cmax (mg/ml) 22.2 ± 0.10*** 19 ± 0.41*** 6.8 ± 0.87 at Tmax ¼ 7.3 h
AUC0–N (mg h/ml) 526.5 ± 42*** 276.9 ± 22*** 249 ± 26 (47 ± 2.1% total AUC0–N)
Cltotal (ml/h) 2.5 ± 0.17**
,*** 4.5 ± 0.28**,***
Vd (ml) 59 ± 7.9**,*** 98 ± 11**,***
t1/2 b (h) 15.3 ± 1.2**
,*** 13.1 ± 0.77**,***
* ¼ Significant difference between 20:1 PolybHb parameter estimates (p < 0.05).
** ¼ Significant difference between 10:1 PolybHb parameter estimates (p < 0.05).
*** ¼ Significant difference between 30:1 PolybHb parameter estimates (p < 0.05).
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concentrations occurred at approximately 1 h in the 10:1
PolybHb group with plasma PolybHb levels reaching 20 ± 2%.
In the 30:1 PolybHb group, maximal plasma oxidized PolybHb
levels occurred at approximately 4 h with levels reaching 27 ±
2%. Total exposures, as determined by AUC0–N (mg h/ml), to
oxidized PolybHb in the 10, 20, and 30:1 PolybHb groups are
shown in Table 2 and suggest the highest total exposure to
ferric PolybHb occurred following transfusion with the 10:1
and 20:1 PolybHb preparations.
Blood pressure response to polybHbs. Systolic blood
pressure (SBP), diastolic blood pressure (DBP), MAP, and
HR are shown in Figures 5A–D. The most dramatic rise in
blood pressure was observed in animals transfused with 10:1
PolybHb. The maximal SBP, DBP, and MAP observed in this
group were 41 ± 5.7% (AUC, 3014 mm Hg), 21 ± 8.0%
(AUC, 1467 mm Hg), and 28 ± 5% (AUC, 2050 mm Hg)
above basal values. HR declined to a minimum of 30 ±
3.0% consistent with peripheral arterial vasoconstriction or
a direct myocardial depressant effect. Conversely, animals
transfused with 30:1 PolybHb demonstrated maximal SBP,
DBP, and MAP of 5.4 ± 2.9% (AUC, 227 mm Hg), 11 ± 0.7%
(AUC, 553 mm Hg), and 8.4 ± 1.0% (AUC, 361 mm Hg)
above basal values. The HR declined to a minimum of 18 ±
4.2% again consistent with some degree of peripheral arterial
vasoconstriction or a direct myocardial depressant effect.
Animals transfused with 20:1 PolybHb demonstrated a mod-
erate effect on blood pressure parameters and HR, consistent
with a molecular size between that of 10:1 and 30:1
PolybHb. For all parameters measured (SBP, DBP, MAP,
and HR) and at each time point (every 5 min over 90 min),
animals in the 10:1 PolybHb group demonstrated significant
changes compared with baseline (p < 0.05) and significant
changes compared with the 30:1 PolybHb group (p < 0.05). The
most substantial rise in blood pressure in all PolybHb transfusion
groups was reflected in the DBP and hence a rise in MAP
reflective of this response. Following transfusion with 30:1
PolybHb, the SBP, DBP, and MAP response was generally mild
and transient returning to basal values within 90 min post-
exposure. Conversely, the 10:1 and 20:1 transfused animals did
not return SBP or DBP to basal values over the time course of
evaluation.
FIG. 2. Plasma concentration versus time data following 50% blood volume for PolybHb transfusion (A–D). Data are presented for total, ferrous, and ferric
heme as the mean ± SEM. The PK parameter estimates for these plots are listed in Table 2.
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PolybHb Molecular Size and the PK-Pharmacodynamic
Relationship
The primary physicochemical property of PolybHb prepa-
rations evaluated in this study was molecular size. Previous
work has suggested that molecular size is one of several
physicochemical determinants that influence PK (Matheson
et al., 2000) and physiological responses to HBOCs (Cabrales
et al., 2009; Faivre-Fiorina et al., 1999). Three primary
exposure parameters (AUC0–N, CLtotal, and Cmax) were all
highly correlated to the molecular size of PolybHb. The
regression analysis of total and ferrous PolybHbs for each of
the three PK parameters is shown in Figures 6A–C. AUC0–N
FIG. 3. Size exclusion chromatographic distribution of polymeric components for each PolybHb preparation in plasma following blood collections (A–C).
(D) The 24 h urinary appearance of Hb following transfusion with each PolybHb preparation.
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values increased linearly with increasing molecular sized
PolybHbs, and these parameters were highly correlated, r2 ¼
0.9998 (Fig. 6A). Total clearance was inversely related to
molecular size (Fig. 6B) with a correlation coefficient of r2 ¼
0.9161, suggesting longer circulatory retention of physically
larger PolybHbs within the range of sizes studied here. Doses
of PolybHbs were not different between groups, as shown in
Table 2, however, Cmax values, which occur immediately
following transfusion increased with larger size PolybHbs, r2 ¼
0.9651 (Fig. 6C). These data suggest that the initial distribution
of PolybHb to nonvascular compartments, for example, the
kidneys, lymphatics, and subvascular spaces may occur more
readily with smaller size PolybHbs. This is supported by
a molecular size–dependent effect on renal excretion of
PolybHbs and subsequently renal tubular iron deposition (see
Fig. 7). Moreover, the present data analysis suggests that
extending circulatory retention can be achieved by optimizing
PolybHb molecular size for our library of PolybHbs.
The PK-blood pressure relationship between AUC0–N, CLtotal,
and Cmax of each PolybHb preparation and their respective
posttransfusion blood pressure responses are shown in
Figures 6D–F. SBP, DBP, and MAP are expressed as AUC0–4 h
such that maximal blood pressures returned to basal values. From
these data, it can be suggested that PolybHb exposure parameters
are most closely related to linear elevations in SBP as observed in
curve fitting of the data. PK-pharmacodynamic relationships
demonstrated a minimum blood pressure effect following trans-
fusion with the PolybHb preparation exhibiting the highest
exposure (i.e., greatest AUC0–N and Cmax and least CLtotal).
Taken together, these data suggest that increasing molecular size
beyond 1300 kDa would not meaningfully influence the SBP,
DBP, or MAP any further.
Renal Exposure to PolybHb Preparations
As shown in Figure 7A, 10:1 PolybHb total dose excreted in
the urine was 35 ± 9.4% (704.9 ± 158lM heme), and of this
concentration, 67 ± 8.0% and 32 ± 8.0% were excreted as
ferrous and ferric (oxidized) Hb, respectively (Fig. 7B). No Hb
was detected in the urines of 20:1 and 30:1 PolybHb-transfused
animals (Fig. 7A).
Renal tissue iron was quantified by the ferrozine method in
lieu of morphometric analysis. Basal tissue iron in the kidneys
was 5.1 ± 0.58 ng/mg and this increased significantly at 24 h
posttransfusion with 10:1 PolybHb (13 ± 0.6 ng/mg), 20:1
PolybHb (11 ± 0.8 ng/mg), and 30:1 PolybHb (9 ± 0.5 ng/mg)
as shown in Figure 7C. Additionally, kidney tissue was stained
using the Perl’s iron method with DAB intensification. This
data show a clear PolybHb size effect on brown granular
staining in the renal cortex (Fig. 7D). This is supported by
increased heme oxygenase immunoreactivity (white arrow
heads) in similar cortical regions where iron deposition was
observed to be greatest (Fig. 7E). This was also confirmed by
an additional Western blot analysis of tissue for heme
oxygenase as shown in Figure 7F. Densitometry (Fig. 7G,
right panel) indicates a dramatic increase in the 10:1 PolybHb-
transfused animal group compared with the control, 20:1
PolybHb-, and 30:1 PolybHb-transfused animal groups. Urine
collections obtained over 24 h demonstrate hemoglobinuria in
the 10:1 PolybHb-transfused animal group, potential latent
excretion of heme within the 9–21 h collection range in the
20:1 PolybHb-transfused animal group. Animals transfused
with 30:1 PolybHb demonstrated no effects consistent with
TABLE 3
Fast (a) and Slow (b) Phase Autoxidation Rate Constants at pH
7.4 and 37C
Hb kox (per hour) a kox (per hour) b
Bovine 0.0088 ± 0.00003 0.00063 ± 0.00009
PolybHb (10:1) 0.0071 ± 0.00003 0.00098 ± 0.00003
PolybHb (20:1) 0.0080 ± 0.00006 0.00090 ± 0.00006
PolybHb (30:1) 0.0089 ± 0.00006 0.0006 ± 0.00001
FIG. 4. (A) Autoxidation of PolybHb in vitro at 37C, * indicates
a significant difference (p < 0.05) versus 10:1 and 20:1. (B) In vivo oxidation
over the initial 24 h of blood sampling posttransfusion, * indicates a significant
difference (p < 0.05) versus 10:1 and 30:1.
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renal filtration of heme-globin, heme, or free iron based on the
quantitative and qualitative analyses.
Renal Tissue Injury
The ultimate effects of renal exposure to Hb, heme, or iron
can result in acute renal toxicity (Zager and Gamelin, 1989).
Data in Figure 8A show hematoxylin and eosin staining for
each of the PolybHb preparations. In the 10:1 PolybHb group,
the proximal and distal renal cortical tubules appeared detached
in localized regions, and tissue was scored as moderate injury
(2 on a scale of 0–3 in four animals). This observation has been
reported to be associated with cytoskeletal disruption and cell
to cell adhesion and regional necrosis (Racusen, 1994). These
observations were not discernible in the 20:1 and 30:1 PolybHb
groups. The effects of PolybHbs on the primary marker of renal
injury, serum creatinine, are shown at 72 h posttransfusion
(Fig. 8B). Mean basal values for serum creatinine were 0.12 ±
0.04 mg/dl. Animals transfused with the 10:1 PolybHb
preparation demonstrated a mild, but significant serum
creatinine level increase to 0.43 ± 0.04 mg/dl, indicative of
acute renal dysfunction when compared with baseline as well
as 20:1 and 30:1 PolybHb-transfused animals. The serum
creatinine levels of the animals transfused with 20:1 and 30:1
PolybHbs demonstrated 72 h serum creatinine levels of 0.20 ±
0.03 mg/dl and 0.17 ± 0.02 mg/dl and were not significantly
different than basal values. These experimental observations
are consistent with histopathological findings.
Alternate Routes of PolybHb Clearance via the Spleen and
Liver
Qualitative surface plasmon resonance data showing the
extent of Hp 1-1 binding to bovine Hb, and each of the
FIG. 5. (A) SBP percentage change from baseline, (B) DBP percentage change from baseline, (C) MAP percentage change from baseline, and (D) HR
percentage change from baseline. For all data points, there was a significant difference (p < 0.05) between PolybHb 10:1 and PolybHb 30:1.
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PolybHbs indicates that the 10:1 PolybHb binds to human Hp
1-1 similarly to unmodified bovine Hb (Figs. 9A and B). The
extent of Hp 1-1 binding to 20:1 and 30:1 PolybHb is
qualitatively less than the 10:1 PolybHb preparation. Heme
oxygenase immunoreactivity in the spleen and liver are shown
in tissue preparations of PolybHb-transfused animals (Figs. 9E
and F). White arrows indicate regions of macrophage
accumulation, particularly in the liver where stained brown,
heme oxygenase positive cells are localized to intrahepatocel-
lular regions. Total iron in the spleen and liver were quantified
via the ferrozine assay and are shown in Figures 9G and H,
respectively. Basal iron in the spleen was 11 ± 1.3 ng/mg and
increased to 23 ± 3.0 ng/mg following 10:1 PolybHb
transfusion, 27 ± 7.2 ng/mg following 20:1 PolybHb trans-
fusion, and 22 ± 1.4 ng/mg following 30:1 PolybHb trans-
fusion. Similarly, clearance via the hepatic route was equally
relevant in PolybHb clearance with basal iron equal to 5.0 ±
0.42 ng/mg and increasing to 19 ± 2.2 ng/mg following 10:1
PolybHb transfusion, 24 ± 1.5 ng/mg following 20:1 PolybHb
transfusion, and 22 ± 1.4 ng/mg following 30:1 PolybHb
transfusion. These data suggest that both the spleen and liver
function as significant clearance organs for all PolybHbs
FIG. 6. (A–C) PolybHb molecular size-PK relationships for exposure parameters: AUC0–N, total clearance, and maximum plasma concentration (Cmax).
(D–F) PK-pharmacodynamic relationships with AUC of blood pressure from 0 to 4 h used as the primary pharmacodynamic endpoint.
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evaluated. Interestingly, no direct toxicity to these organs
systems was observed suggesting an inherent capability for
both spleen and liver to effectively clear chemically modified
Hb with minimal or no tissue injury. This would suggest that
optimizing clearance through these organs may be inherently
safer and would limit renal exposure to globin, heme, and iron.
DISCUSSION
To date, limited approaches have been studied to down
select HBOC candidates from libraries of chemically modified
Hbs intended for therapeutic purposes. The primary endpoint(s)
of the most extensive studies reported to date have focused on
evaluation of NO binding to modified Hb (Doherty et al.,
1998). The potential results of this interaction are increased
systemic vascular resistance, depressed cardiac output, and
therefore an increase in systemic hypertension, which are the
most well known safety signals associated with this class of
therapeutics (Yu et al., 2009). As a result, the primary focus of
candidate selection studies has been on NO reactivity with the
Hb component of HBOCs and the hemodynamic effects.
A series of studies was conducted with recombinant Hb or
myoglobin analogs site specifically modified within the heme
pocket to slow the rate of NO dioxygenation. Selection was
based biochemically on the slowest NO reactivity with
recombinant Hb (i.e., to limit NO consumption) and correlation
with in vivo hemodynamic responses (Doherty et al., 1998;
FIG. 7. (A) Percentage of dose excreted in urine, < LOQ (less than the assay limits of quantitation). (B) Percentage of excreted Hb in the ferrous (Hb-Fe2þ)
and ferric (Hb-Fe3þ) oxidation states, < LOQ (less than the assay limits of quantitation). (C) nanograms (ng) of kidney tissue iron per mg of tissue, *significant
difference (p < 0.05) compared with nontreated animals, **significant difference (p < 0.05) between 30:1 and 20:1 PolybHb and between 30:1 and 10:1 PolybHb.
(D) Perl’s iron staining with DAB intensification of kidney and (E) heme oxygenase (HO-1) immunohistochemistry of renal cortical tubular cells, white arrow
heads indicate HO-1 positive regions. Scale bars equal to 1 cm. (F) Urine collected over eight 3 h intervals for 24 h. (G) Western blot analysis of HO-1 expression
in renal cortical tissue (left) and densitometry of band intensity (right). *Significant difference (p < 0.05) compared with nontreated animals, **significant
difference (p < 0.05) between 10:1 and 20:1 PolybHb, and ***between 10:1 and 30:1 PolybHb.
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Dou et al., 2002; Olson et al., 2004). Although this approach
down selected for optimal hemodynamic characteristics of
a candidate Hb for use as an HBOC, our present work is
designed to expand on these concepts and evaluate a feasible
in vivo down selection process using several criteria critical to
HBOC safety. The present work was aimed at expanding
existing down selection techniques for small libraries of HBOCs
in order to optimize (1) PKs, (2) in vitro/in vivo oxidation
(defined by Hb iron transition from Fe2þ/ Fe3þ, metHb), (3)
systemic blood pressure, and also (4) evaluate primary routes of
clearance, and (5) determine the potential for acute renal toxicity.
PK parameter estimates of HBOCs determined from animal
studies could effectively define the desired exposure for
specific indications in humans, given that HBOC volume of
distribution is largely limited to the central compartment and that
clearance occurs via two primary mechanisms (renal filtration
and reticulo-endothelial system). HBOCs designed to replace the
use of blood should theoretically demonstrate long exposure
times to mimic the duration of RBCs circulation. In the present
study, data showed that the 30:1 PolybHb preparation
demonstrated the most extensive circulating t1/2 and exposure
related PK estimates, with an increased Cmax, AUC0–N, and
slower Cl compared with the other PolybHbs tested.
Although defining the optimal PK criteria is critical to
intended clinical indication, oxidation of the HBOC in
circulation, potential HBOC-mediated effects on blood pres-
sure, routes of HBOC clearance, and HBOC-induced tissue
injury are critical areas of investigation. The present study was
performed in a guinea pig model of ET to approximate the
plasma reductive capacity of humans. Guinea pigs, like humans,
represent a species incapable of endogenous production of
ascorbic acid due to an evolutionary loss of the final enzyme in
its biosynthesis (Chatterjee, 1973; Nandi et al., 1997). Long
circulating HBOCs are maintained in their nonoxidized form by
the presence of plasma reducing agents such as ascorbic acid,
which are capable of maintaining HBOC functional oxygen
carrying capability and limiting pro-oxidant-induced toxicity
(Buehler et al., 2007; Butt et al., 2010; Butt et al., 2011). Our
in vitro oxidation studies and PK analyses of the transition states
of heme iron within the circulating HBOC polymers allowed us
to determine the propensity for oxidation and total circulatory
exposure to oxidized HBOC. Based on our data, PolybHbs could
be placed in order of most to least prone to oxidation as follows;
20:1 > 40:1 > 10:1 > 30:1. Interestingly, the experimental
observations were independent of HBOC molecular size, PK
characteristics, or biochemical properties. These data may further
stress the importance of studies that define propensity for HBOC
oxidation in human predictive species.
Evaluation of systemic blood pressure in response to PolybHb
preparations suggested that molecular size was a critical attribute
to minimizing the HBOC-related elevation of SBP, DBP, and
MAP. The present study demonstrates that PolybHbs could be
placed in order of propensity to induce a hypertensive response as
follows; 10:1 > 20:1 > 40:1 ¼ 30:1. This safety pharmacology
parameter was clearly correlated to molecular size and with the
exception of the 40:1 preparation correlated positively with Cmax
and AUC0–N and inversely correlated with Cl.
Glomerular filtration of Hb heterodimers is a primary route of
clearance for both Hb and certain HBOC preparations (Caccia
et al., 2009; Portoro et al., 2008). The extent of posttransfusion
circulatory breakdown or pretransfusion unstable tetrameric Hb
in chemically modified Hb preparations ultimately determines
the extent of renal excretion (Caccia et al., 2009). The result of
Hb renal excretion is observed as hemoglobinuria, which results
in heme oxygenase activation, iron deposition, and oxidation of
renal tissue protein and DNA (Boretti et al., 2009; Butt et al.,
2010). More extensive damage to kidney tissue can result from
renal tubular or glomerular injury with elevation in serum
creatinine. These effects are associated with acute and potentially
chronic renal failure following Hb and its breakdown products
deposition within the kidneys (Zager and Gamelin, 1989). Data
from the present study suggest that all PolybHbs were generally
stable in circulation with the exception of the 10:1 preparation,
which demonstrated extensive posttransfusion hemoglobinuria.
This led to increased renal HO-1 expression suggesting high
level Hb deposition in renal parenchyma and extensive iron
deposition. The acute Hb exposures to kidneys lead to changes in
renal proximal and distal tubule morphology and an elevation in
circulating creatinine levels. These data suggest that the larger
molecular size PolybHbs tested were physically more stable in
circulation and directed excretion away from renal filtration.
Chemically modified Hb solutions have been shown to
interact with endogenous clearance pathways associated with
the reticulo-endothelial system (Buehler et al., 2008).
Interaction with the Hb scavenger protein haptoglobin (Hp)
FIG. 8. (A) renal cortical injury as a result of transfusion with PolybHb
10:1, 20:1, and 30:1. Scale bars equal to 1 cm. (B) serum creatinine values at
baseline and 72 h posttransfusion. *Indicates significant differences (p < 0.05)
comparing time points and groups.
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is the initial event occurring in circulation to facilitate
clearance of chemically modified Hb (Buehler et al., 2008).
Uptake by peripheral and resident tissue macrophages
functions as a primary uptake process for Hb-Hp complexes
and alternatively as a secondary route of clearance for Hb
and chemically modified Hb independent of Hp has been
shown (Schaer et al., 2006). In the present study, the 10:1
PolybHb bound to Hp more effectively than the other
PolybHbs tested. Iron deposition was highest in the spleen
and liver suggesting that the 10:1 PolybHb preparation had
one molecular component excreted via the kidneys and
second cleared via spleen and liver, whereas the larger
molecular sized PolybHbs were excreted exclusively by
spleen and liver.
FIG. 9. (A–D) Surface plasmon resonance binding of bHb, 10:1 PolybHb, 20:1 PolybHb, and 30:1 PolybHb. (E–F) Heme oxygenase-1 (HO-1)
immunohistochemistry of spleen and liver. Scale bars equal to 1 cm. (G–H) Spleen and liver iron, *indicates significant differences (p < 0.05) between all PolybHb
groups and nontreated (NT) animals.
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In conclusion, relevant experimental observations suggested
that oxidation was a molecular size–independent event,
whereas circulatory retention was molecular size dependent
within a range. Most notable was that mean molecular sizes
below 100 kDa promoted renal excretion, whereas very large
molecular sizes (> 5000 kDa) also promoted more rapid
clearance, albeit via alternate routes, but likely involving
reticulo-endotheial system activation. Blood pressure elevation
was found to be highly dependent on molecular size and renal
toxicity was limited to the lowest molecular size preparation.
Our data suggest that the 30:1 PolybHb preparation would be
most optimal to pursue as a long acting HBOC. Figure 10
illustrates the rationale for selection of the 30:1 preparation
for further proof of concept and good laboratory practice
toxicology evaluation. Moreover, the approach illustrated in
Figure 10 to HBOC down selection represents a novel method
to optimize for intended indication exposure requirements and
limit the potential for toxicity in later preclinical and clinical
development.
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